Articles tagged with Myeloma
Researchers have discovered a new mechanism of antitumor response of Natural Killer (NK) cells in myeloma, utilizing histones. Histones bind to CD138 receptors on myeloma cells, promoting tumor cell aggregation and enhancing the recruitment of T lymphocytes, thereby increasing antitumor activity.
A study found that patients with monoclonal gammopathy of undetermined significance (MGUS), a pre-cancerous condition, made twice as many hospital visits than others of the same age. Researchers believe this could help diagnose myeloma at an earlier stage and improve treatment outcomes.
A new study has found that long-term therapy with lenalidomide doubles remission duration and improves survival in younger patients by almost 8%. The treatment is also shown to prolong the average remission time by more than two years in younger patients.
Researchers at the Weizmann Institute of Science have created a new method to sequence individual cells from patient blood or bone marrow, capturing specific gene programs active in each cell. This allows for more precise diagnosis and treatment of multiple myeloma by identifying unique genetic blueprints for each patient.
Researchers at Dana-Farber Cancer Institute have made significant advances in understanding the progression of multiple myeloma from precursor conditions, suggesting potential new treatments. The study found that immune system cells in patients with precursor conditions undergo changes that affect disease progression, and a novel combi...
Researchers identified three specific subtypes of myeloma linked to higher risk in African-Americans due to genetic translocations and increased African ancestry. The study provides insight into the mechanisms of health disparity and potential treatment strategies for this population.
Researchers found a simple combination of two blood tests can diagnose myeloma in GPs, enabling earlier diagnosis and treatment. The study analyzed over 2,700 cases and suggested integrating a system to alert clinicians to relevant symptoms or changes in blood parameters.
Researchers discovered that a multiple sclerosis drug can mitigate the painful side effect of cancer treatment bortezomib. Fingolimod, an approved multiple sclerosis medication, blocks the production of molecules causing nerve damage and alleviates neuropathic pain.
Australian researchers have discovered a new class of anti-cancer agents targeting MCL-1, which may be effective in treating multiple myeloma. The majority of myelomas rely on MCL-1 to stay alive, and inhibiting it has shown potential as a treatment approach for the majority of patients.
Researchers discovered changes in bone marrow that can develop into myeloma have already taken hold in the preceding condition MGUS. Early medical intervention may prevent this incurable type of cancer from taking root.
A research team has identified the AF1q protein as an adverse prognostic factor for multiple myeloma, particularly in cases where extramedullary disease is present. The study found that high expression of AF1q is associated with a higher incidence of EMD.
Researchers have identified a new therapeutic target for multiple myeloma, targeting CDK4 and ARK5 proteins. The compound ON123300 showed potent cytotoxicity against myeloma cells while sparing normal peripheral blood cells.
A SWOG trial shows that adding bortezomib to lenalidomide and dexamethasone therapy in early treatment improves remission time and life expectancy for myeloma patients by about a year, compared to the standard two-drug regime.
Researchers identified key metabolic changes that occur in patients with myeloma and those at risk of developing the disease. The findings suggest a potential drug target to prevent progression from benign MGUS to cancerous myeloma.
Researchers identified abnormal miRNA levels in patients with myeloma, detectable in peripheral blood, suggesting a potential biomarker for disease progression. Analysis revealed unique miRNA signatures indicative of myeloma, including the let-7 family members.
A new genetic test identified nine key genes that can predict which myeloma patients are at risk of developing aggressive disease, leading to the development of personalized treatment plans. The test shows promise in identifying patients who may benefit from intensive treatment and improving survival rates.
A comprehensive review published in The Lancet provides guidance on treating multiple myeloma, including established and novel therapies. New approaches to paralyze cancer cells and attack malignant cells are also introduced.
A study at Dana-Farber Cancer Institute found that a narrow subset of myeloma cells is responsible for metastasis. The researchers identified 11 genes with functional roles in metastasis and proposed these as potential targets for therapies.
The International Myeloma Working Group has updated its criteria for diagnosing multiple myeloma, allowing for earlier diagnosis without symptoms. The new guidelines incorporate validated biomarkers to identify patients at risk of progression, enabling targeted therapy and improved patient outcomes.
A new study reveals the link between obesity and increased risk of myeloma, a cancer of plasma cells. The researchers found that adiponectin, a protective protein, can be used to suppress fatty acid production in myeloma cells, leading to their demise.
A new whole-body MRI scan has improved the treatment of myeloma cancer by accurately imaging the spread of cancer throughout the bone marrow. The scan showed high accuracy in identifying patient response to treatment, reducing the need for painful biopsies.
A genetic variant linked to a cell's internal clock has been associated with myeloma, a common type of blood cancer. The study identified four new genetic variants linked to myeloma, bringing the total number to seven.
The discovery of the Mcl-1 gene's critical role in keeping antibody-producing cells alive could lead to better treatments for diseases like myeloma and chronic immune disorders. Without this gene, plasma cells die within two days.
Researchers present promising results from a Phase II study on quizartinib, a targeted therapy that may turn treatment-resistant leukemia into manageable conditions. The study shows great potential in turning fatal disease subtypes into chronic conditions with regular treatment.
Researchers at Dana-Farber Cancer Institute have created a peptide cocktail that sparks a stronger diverse immune response in laboratory culture than individual peptides. The combination of four antigenic peptides is believed to provide an effective therapeutic application for patients with multiple myeloma and related diseases.
Researchers developed a small molecule called JQ1 that targets the bromodomain protein BRD4, switching off the MYC gene and slowing down cancer cell division. The study showed promising results in treating multiple myeloma and other cancers driven by MYC.
Researchers have identified key molecules in multiple myeloma that can trigger expression of the P53 tumor suppressor gene, slowing cell growth and leading to death. The study suggests re-activating these microRNAs could provide a new treatment strategy for the disease.
The Arizona Myeloma Network recognized Dr. Jeffrey Trent, President of the Translational Genomics Research Institute (TGen), for his organization's support of cancer patients and events such as the 'All Cancers' run. This recognition acknowledges TGen's involvement in patient-advocacy organizations like AzMN.
A recent study found that lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and lower toxicity than traditional high-dose therapy in newly diagnosed myeloma patients. The treatment regimen shows acceptable toxicity and low early mortality, making it a viable option for these patients.
Researchers discovered that plasmacytoid dendritic cells assist in the growth of multiple myeloma cells by promoting their survival and shielding them from drugs. Compounds targeting pDCs restore immune system function, stopping myeloma cell growth.
A recent study published in Leukemia suggests that genetic changes in response to environmental toxins may contribute to the development of multiple myeloma. The study found associations between specific DNA sequence variations and an increased risk of bone disease in myeloma patients.
Recent research has shown a significant improvement in two-year survival rates for patients with multiple myeloma, from 48-66% in the 1980s to around 90% today. Potent new drugs have been instrumental in this breakthrough, offering improved outcomes without severe side effects.
Findings from two large clinical trials demonstrate significant improvement in patients with multiple myeloma who received Revlimid, an oral cancer drug, compared to those receiving a placebo. The study showed improved median survival and response rates, offering new hope for patients with this challenging disease.
C-reactive protein (CRP) is a potential target for cancer treatment, promoting myeloma cell proliferation and protecting against chemotherapy-induced apoptosis. CRP enhances secretion of IL-6 and activates PI3K/Akt pathways, supporting tumor cell survival.
Researchers at Mayo Clinic Cancer Center have discovered that chaetocin, a by-product of common wood mold, is more effective than current therapies in killing multiple myeloma cells. The study found chaetocin induces oxidative stress and selectively kills myeloma cells with superior efficacy.
Researchers with Bank On A Cure identified genetic pathways associated with venous thromboembolisms in patients treated with thalidomide for multiple myeloma. These findings may lead to screenings and tailored interventions to prevent blood clots, as well as the development of new treatments.
Studies presented at the 2006 Annual Meeting of the American Society of Hematology demonstrate significant gains in treating multiple myeloma and related blood cancers. New treatment regimens, including THALOMID, VELCADE, and REVLIMID, show promising results in both newly diagnosed and relapsed patients.
Researchers identified four genetic subtypes of multiple myeloma, each with distinct gene signatures that predict patient outcomes. The findings provide a clear path for targeted therapies and could lead to improved treatments for this incurable blood cancer.
The study found that Rev/Dex reduced myeloma cancer protein levels by over half in 91% of patients, with manageable side effects and a rapid response time. This oral treatment offers an attractive alternative to traditional intravenous therapies.
Researchers found that a combination of thalidomide and dexamethasone is as effective as standard intravenous chemotherapy in treating newly diagnosed multiple myeloma. A newer analog, CC-5013 (lenalidomide), showed promise with fewer side effects.
A recent finding reveals a frequent abnormal cellular event occurring in about half of all myeloma cases, identifying c-maf as an attractive target for therapeutic intervention. Inhibition of c-maf function blocks tumor formation in mice, suggesting its potential as a novel target for future therapies.
A phase 2 clinical trial found that bortezomib responded positively in 193 relapsed patients, including seven with undetectable myeloma protein and 12 with detectable protein only with immunofixation. The results confirmed significant clinical benefits from therapy.
A Phase II study found that the DVd regimen showed a high response rate of 88%, with 12% achieving complete response. The treatment was well-tolerated, with the most common Grade 3 or 4 toxicity being palmar-plantar erythrodysesthesia. Improved patient education and prevention measures reduced toxicity incidence.
Researchers at Mayo Clinic have discovered that thalidomide can effectively delay the progression of early-stage multiple myeloma in some patients. In a phase II clinical trial, approximately 80% of patients remained progression-free after one year and 63% were still free from disease progression after two years.
The Mayo Clinic study found that thalidomide can stop or slow the progression of multiple myeloma in patients newly diagnosed with this cancer. Thalidomide was previously used to treat advanced myeloma, but this is the first published report documenting its effectiveness as a first-line treatment for early-stage multiple myeloma.
PS-341, a proteasome inhibitor, has shown promising results in treating multiple myeloma and non-Hodgkin's lymphoma. The Phase I clinical trial found one complete response and several partial responses among patients, indicating the drug's potential as a treatment option.